Pfizer (PFE) Acquisitions (2009 - 2023)

Pfizer (PFE) posted quarterly Acquisitions of $43.4 billion for Q4 2023, up 173520.0% sequentially from $25.0 million in Q3 2023.

Pfizer (PFE) Acquisitions (2009 - 2023) Analysis & Trends

Pfizer has disclosed Acquisitions across 10 years of filings, most recently posting $43.4 billion for Q4 2023.

In Q4 2023, Acquisitions changed N/A year-over-year to $43.4 billion; the TTM figure through Sep 2024 stood at $43.4 billion (up 594.88% YoY), while the FY2025 annual figure was $6.9 billion, changed N/A from the prior year.
Acquisitions rose to $43.4 billion in Q4 2023, from $25.0 million in the prior quarter.
Over the last five years, Acquisitions for PFE reached as high as $43.4 billion in Q4 2023 and fell as low as $25.0 million in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Acquisitions (Qtr)
1	Eli Lilly	1,066.16 Bn	1,060.88 Bn	16.22 Bn	-
2	Johnson & Johnson	611.69 Bn	589.64 Bn	15.96 Bn	-
3	AbbVie	444.34 Bn	434.99 Bn	10.78 Bn	-
4	Astrazeneca	284.94 Bn	277.05 Bn	12.61 Bn	7.56 Bn
5	Merck	224.23 Bn	218.58 Bn	12.09 Bn	8.78 Bn
6	Amgen	195.12 Bn	183.08 Bn	5.87 Bn	-
7	Gilead Sciences	156.45 Bn	148.73 Bn	5.52 Bn	109.00 Mn
8	Pfizer	136.01 Bn	123.24 Bn	-1.21 Bn	-
9	Novartis Ag	113.45 Bn	113.67 Bn	-	-
10	Biogen	30.87 Bn	26.59 Bn	1.82 Bn	-

Download Data